— Know what they know.
Not Investment Advice

BNBX NASDAQ

BNB Plus Corp.
1W: -55.6% 1M: -65.1% 3M: -72.2% YTD: -89.2%
$0.16
Last traded 2026-07-13 — delisted
NASDAQ · Healthcare · Biotechnology · $210492 mcap · 1M float · 84.52% daily turnover · Short 4% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.2M
52W Range0.11-7.15
Volume4,589,063
Avg Volume887,952
Beta0.55
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOClay D. Shorrock
Employees26
SectorHealthcare
IndustryBiotechnology
IPO Date2025-10-08
Websitebnbx.io
50 Health Sciences Drive
Stony Brook, NY 11790
US
631 240 8800
About BNB Plus Corp.

BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.

Recent Insider Trades

NameTypeSharesPriceDate
Shorten Richard Lee A-Award 100,000 $0.15 2026-09-14
Larsen Todd A-Award 100,000 $0.15 2026-09-14
Lee Lok A-Award 100,000 $0.15 2026-09-14
Lee Lok 0 — 2026-09-03
Larsen Todd 0 — 2026-09-03

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms